CD47 is emerging as a promising intervention point in Cancer therapy. Head and Neck Squamous Cell Carcinoma:  Anti-CD47 treatment enhances anti-tumor T-cell immunity and improves immunosuppressive environment in head and neck squamous cell carcinoma.  Wu L, Sun ZJ, et al. (2018) Oncoimmunology 7(4): e1397248. Doi: 10.1080/2162402X.2017.1397248. Glioma:  Blocking the CD47-SIRPα axis by delivery of anti-CD47 […]

Anti-GITR is proving to be another useful intervention checkpoint in cancer therapy.   Abstract 3813: Development of JNJ-64164711, a low fucose anti-GITR antibody for enhanced depletion of tumor regulatory T cells (Tregs) Cam V. Holland, John Kehoe, Judith Hailey, Rupesh Nanjunda, Eilyn Lacy, Robin Ernst, Di Zhang, Sam Wu, Alexey Teplyakov, Weimin Li, Michelle Kinder,

Interfering with the CD279(PD-1) – CD274(PD-L1) axis has shown great promise in restoring anti-cancer T cell function.  This Pittsburgh research group has used a similar approach in a mouse HSV-1 model to improve T cell mediated viral clearance from the immunologically sequestered cornea.   “PD-L1/B7-H1 Inhibits Viral Clearance by Macrophages in HSV-1–Infected Corneas” Sohyun Jeon,

Visit Ancell at Booth #231 at the American Association of Immunology annual meeting in Austin Texas May  4 – 8!

ANC28.1 mAb used as a Control in a Modified Chandler-loop model developed to screen and assess drug toxicity This system could potentially prevent disastrous clinical human trials like the TGN1412 (anti-CD28) one.   “Extracorporeal human whole blood in motion as a tool to predict first-infusion reactions and mechanism-of-action of immunotherapeutics”  E A K Fletcher, S

In CD28 knockout mice, TFR cells have diminished suppressive ability, and B cells cause systemic inflammation. “B Cells Drive Autoimmunity in Mice with CD28-Deficient Regulatory T Cells” Ruan Zhang, Laurence A. Turka, et al J Immunol December 15, 2017, 199 (12) 3972-3980; DOI: https://doi.org/10.4049/jimmunol.1700409

CD244 (NK cell Activation Inducing Ligand, NAIL, NKCR 2B4, Nmtk) is a member of the Signaling Lymphocyte Activation Molecule (SLAM) family, which also includes CD2. It is expressed on NK cells as well as a sub set of T cells.  The type of signaling is controlled by the prevalence and type of intracellular adaptor proteins.

Visit Ancell at booth T13 at the Autumn Immunology Conference Fri Nov 17 to Mon Nov 20th !  We are proud to fund an Undergrad Outreach Sponsorship, as well as a Wallace Diversity Sponsorship.

“PD-1 Blockade Promotes Epitope Spreading in Anti-cnacer CD8+ T cell Reponses by Preventing Fratricidal Death of Subdominant Clones To Relieve Immunodomination”  Arash Memarnejadian, S M Mansour Haeryfar, et al. (Nov 2017) J Immunol 199(9): 3348-59.  https://doi.org/10.4049/jimmunol.1700643.  PMID: 28939757   Often over time, an anti-Cancer immune response narrows into a few dominant (high affinity) CD8+ T

New Ancell TIGIT-muIg binds to CD155 on U-937 cells and to recombinant CD155-muIg in EIA!   The TIGIT – CD155 regulatory pathway is emerging as an important element of immune function.  Studies using knockout mice demonstrate that this pathway is important in optimal NK effector cell function (activation and/or tolerance) (1) There is significant potential